ArticleMolecular psychiatry2017
Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1.
Article in Molecular psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response.Journal of clinical laboratory analysis · 2022Pooled it
- A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder.Addiction science & clinical practice · 2021Pooled it
- Analysis of genetic and clinical factors associated with buprenorphine response.Drug and alcohol dependence · 2021Pooled it
- Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans.Biological psychiatry · 2018Pooled it
- OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: a randomized, double-blind, placebo-controlled study.The pharmacogenomics journal · 2020Trial
- Transcription factors implicated in substance use disorder, from immediate early genes to altered gene expression.Brain research · 2026Review
- Association ofBalkan journal of medical genetics : BJMG · 2025Article
- Genetic Associations of Persistent Opioid Use After Surgery Point to OPRM1 but Not Other Opioid-Related Loci as the Main Driver of Opioid Use Disorder.Genetic epidemiology · 2025Article
- Chronic Pain and Substance Use Disorders: A Brief Narrative Review of Genetic, Neurobiological, and Environmental Contributions to Comorbidity.Journal of psychiatry and brain science · 2025Article
- IUPHAR Review: New strategies for medications to treat substance use disorders.Pharmacological research · 2024Review
- A genome-wide association, polygenic risk score and sex study on opioid use disorder treatment outcomes.Scientific reports · 2023Article
- Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome.Pediatric research · 2023Article
- Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond.Scientific reports · 2022Article
- Association of the D-amino acid oxidase gene with methadone dose in heroin dependent patients under methadone maintenance treatment.Journal of human genetics · 2022Article
- Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies.Biomedicines · 2021Review
- Genome-Wide Correlation of DNA Methylation and Gene Expression in Postmortem Brain Tissues of Opioid Use Disorder Patients.The international journal of neuropsychopharmacology · 2021Article
- Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry.Molecular psychiatry · 2021Article
- Genetics of substance use disorders in the era of big data.Nature reviews. Genetics · 2021Review
- Genetics of substance use disorders: a review.Psychological medicine · 2021Article
- Whole-Exome Sequencing to Identify Potential Genetic Risk in Substance Use Disorders: A Pilot Feasibility Study.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
Opioids are very effective analgesics, but they are also highly addictive. Methadone is used to treat opioid dependence (OD), acting as a selective agonist at the μ-opioid receptor encoded by the gene OPRM1. Determining the optimal methadone maintenance dose is time consuming; currently, no biomarkers are available to guide treatment. In methadone-treated OD subjects drawn from a case and control sample, we conducted a genome-wide association study of usual daily methadone dose. In African-American (AA) OD subjects (n=383), we identified a genome-wide significant association between therapeutic methadone dose (mean=68.0 mg, s.d.=30.1 mg) and rs73568641 (P=2.8 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.